Dana-Farber Cancer Institute

Bruce Springsteen announced that his wife, Patti Scialfa, is in remission from multiple myeloma, a cancer she has lived with for over eight years. He shared the update during the Pan-Mass Challenge, a cancer fundraising event, and Scialfa discussed her new normal of managing the disease.

Experimental drug daraxonrasib shows promise in treating pancreatic cancer, with clinical trial participants experiencing extended survival times. Former U.S. Senator Ben Sasse, part of the trial, reported significant tumor reduction. The drug targets RAS gene mutations common in pancreatic cancer and is under FDA priority review.

Paul Richardson, MD, of the Dana-Farber Cancer Institute in Boston presented trial results for a novel oral treatment, as quoted in a MedPage Today article. The quote references an informal tone before discussing the scientific findings.

A new experimental pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy in a clinical trial. The drug targets a mutated protein present in over 90% of pancreatic cancer cases and showed fewer severe side effects, with patients reporting better quality of life.

A new experimental pill, daraxonrasib, nearly doubled survival time for patients with advanced pancreatic cancer compared to chemotherapy, with fewer severe side effects. The drug, which targets a mutated protein common in pancreatic cancer, is being fast-tracked for FDA review and has shown improved quality of life for patients.

A new pancreatic cancer pill called Daraxonrasib has shown promise in early testing, with about 30% of patients seeing a positive response and 90% having their cancer either shrink or stop getting worse. The pill is designed to block multiple active cancer signals that help tumor cells grow. The clinical trial was led by the Dana-Farber Cancer Institute.